☰

Adding cediranib to chemotherapy improves progression-free survival for metastatic or recurrent cervical cancer, phase II trial shows




For patients with cervical cancer that has recurred after treatment or has spread elsewhere in the body, adding the experimental drug cediranib to standard chemotherapy improves tumour shrinkage and adds a modest improvement in progression-free survival, researchers report at the ESMO 2014 Congress in Madrid.

Fuente : http://www.alphagalileo.org/ViewItem.aspx?ItemId=1...

Sábado, 27 de Septiembre 2014
Jueves, 1 de Enero 1970
1

1 1
Otros artículos de esta sección